Haematopoietic cytokines in the biology and treatment of acute myeloid leukaemia: Perspectives and controversies (Review)

Oncology Reports

Volumn 4, Issue 6, 1997, Pages 1141-1149

  Hassan, Hassan Tawhid ^a   Zander, Axel Rolf ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute leukemia; Colony stimulating factor; Interleukin

Indexed keywords

ALPHA INTERFERON; AMSACRINE; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; CYTARABINE; CYTOKINE; DAUNORUBICIN; ENOCITABINE; ETOPOSIDE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; INTERLEUKIN 11; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MILODISTIM; MITOXANTRONE; PLACEBO; STEM CELL FACTOR; THROMBOPOIETIN; TIOGUANINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 21Q; CHROMOSOME ABERRATION; CLINICAL TRIAL; EDEMA; FEVER; HUMAN; HUMAN CELL; HYPERTENSION; INFECTION; LEUKEMIA CELL; NEUTROPENIA; OLIGURIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0030884975     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Burnett AK and Eden OB: The treatment of acute leukaemia. Lancet 349: 270-275, 1997.
2. Hayhoe FGJ and Rees JKH: The leukaemias. In: Blood Disorders in the Elderly. Denham MJ and Chanarin I (eds). Churchill Livingstone, Edinburgh, pp188-207, 1985.
3. Hassan HT and Rees JKH: Relation between age and blast cell differentiation in acute myeloid leukaemia patients. Oncology 47: 439-442, 1990.
4. Giannoulis N, Ogier C, Hast R, Lindbolm B, Sjogren AM and Reizenstein P: The difference between young and old patients in characteristics of leukaemia cells. Older patients have cells growing excessively in vitro with low antigenicity despite high HLA-DR antigen. Am J Hematol 16: 113-118, 1984.
5. Raza A, Preisler HD, Day R, et al: Direct relationship between remission duration in acute myeloid leukaemia and cell cycle kinetics: a leukaemia intergroup study. Blood 76: 2191-2197, 1990.
6. Fialkow PJ, Singer JW, Raskind WW, et al: Clonal development stem cell differentiation and clinical remissions in acute nonlymphocytic leukaemia. N Engl J Med 317: 468-473, 1987.
7. Johnson PRE and Liu Yin JA: AML in elderly patients: biology and treatment. Br J Haematol 83: 1-6, 1993.
8. Champlin RE, Gajewski JL and Golde DW: Treatment of AML in the elderly. Semin Oncol 16: 51-56, 1989.
9. Hassan HT: Differentiation induction therapy: an alternative for treatment of elderly patients with acute myelogenous leukaemia. J Clin Exp Gerontol 10: 63-73, 1988.
10. Rees JKH, Gray RG and Wheatley K: Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principle report of the Medical research Council AML9 study. Br J Haematol 94: 89-98, 1996.
11. Hassan HT: Age and the biology of acute myeloid leukemia. Ann Hematol 64: 157-159, 1992.
12. Löwenberg B and Touw IP: Hematopoietic growth factors and their receptors in acute leukemia. Blood 81: 281-292, 1993.
13. Young DC, Wagner K and Griffin JD: Constitutive expression of the GM-CSF in AML. J Clin Invest 79: 200-206, 1987.
14. Griffin JD, Rambaldi A, Vellenga E, et al: Secretion of Interleukin-1 by AML cells in vitro induces endothelial cells to secret colony stimulating factors. Blood 70: 1218-1221, 1987.
15. Cheng GY, Kellecher CA, Miyauchi J, et al: Structure and expression of genes of GM-CSF and G-CSF in blast cells from patients with AML. Blood 71: 35-41, 1988.
16. Mayani H, Shen SY, Guilbert LJ, et al: Effect of rhCSF-1 on human hemopoiesis in long-term cultures from patients with AML. Leukemia 5: 8-13, 1991.
17. Young DC, Demetri GD, Ernst TJ, Cannistra S and Griffin JD: In vitro expression of colony stimulating factor genes by human AML cells. Exp Hematol 16: 378-382, 1988.
18. Oster W, Cicco NA, Klein H, Hirano T and Kishimoto T: Participation of cytokine IL-6, TNF-alpha and IL-1 beta secreted by AML blasts in autocrine and paracrine leukemia growth control. J Clin Invest 84: 451-457, 1989.
19. Van der Schoot CE, Jansen P, Poorter M, et al: Interleukin-1 and interleukin-6 production in acute leukaemia with monocytoid differentiation. Blood 74: 2081-2087, 1989.
20. Tobler A, Moser B, Dewald B, et al: Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 82: 2517-2525, 1993.
21. Lemoli RM, Fogli M, Fortuna A, et al: Interleukin-11 (IL-11) acts as a synergistic factor for the proliferation of human myeloid leukaemic cells. Br J Haematol 91: 319-326, 1995.
22. Migliaccio G, Migliaccio AR, Ruscetti S and Adamson JW: The growth of erythroleukemia cells is mediated by autocrine production of a factor with biological activity similar to interleukin-3. Blood 73: 1770-1777, 1989.
23. Mitjavila MT, Le Codevic JP, Navarro S and Villeval JL: Autocrine stimulation by erythropoietin and autonomous growth of human erythroleukemia cells in vitro. J Clin Invest 88: 789-797, 1991.
24. Brach MA, Löwenberg B, Montovani L, Schwulea U, Mertesimann R and Herrmann F: Interleukin-6 as an intermediate in IL-1-induced proliferation of leukaemic human megakaryoblasts. Blood 76: 1972-1979, 1990.
25. Russell NH, Hunter AE, Bradbury D, Zhu YM and Keith F: Biological features of leukaemic cells associated with autonomous growth and reduced survival in AML. Leuk Lymphoma 16: 223-239, 1995.
26. Nara N, Tanikawa S, Nagata K, et al: Effects of stem cell factor on the in vitro growth of leukemic blast progenitors in acute non-lymphocytic leukemia. Int J Hematol 58: 27-35, 1993.
27. Delwel R, Salem M, Dorssers L, et al: Growth regulation of human AML: effects of five recombinant hematopoietic factors ina serum-free culture system. Blood 72: 1944-1950, 1988
28. Vellenga E, Ostapovicz D, O'Rourke B and Griffin JD: Effects of recombinant IL-3, GM-CSF and G-CSF on the proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1: 584-589, 1987.
29. Matsumura I, Kanakura Y, Kato T, et al: Growth response of AML cells to recombinant human thrombopoietin. Blood 86: 703-709, 1995.
30. Tsao CJ, Cheng TY, Chang SL, et al: Effects of GM-CSF and IL-6 on the growth of leukemic blasts in suspension culture. Int J Cell Cloning 10: 166-172, 1992.
31. Salem M, Delwel R, Touw I, Mahmoud LA, Elbasousy EM and Löwenberg B: Modulation of colony stimulating factor (CSF) dependent growth of AML by TNF. Leukemia 4: 37-42, 1990.
32. Tessier N and Hoang T: Transforming growth factor β inhibits the proliferation of the blast cells of AML. Blood 72: 159-164, 1988.
33. Suzuki T, Bessho M, Hirashima K, et al: Enhancement by TGF-β1 of the proliferation of leukemic blast progenitors stimulated with IL-3. J Cell Physiol 148: 396-405, 1991.
34. Imai Y, Nagata K, Suzuki T, et al: Effects of recombinant IL-4 on the growth and differentiation of blast progenitors stimulated with G-CSF, GM-CSF and IL-3 from AML patients. Br J Haematol 78: 173-178, 1991.
35. Murohashi I and Hoang T: Interferon-gamma enhances growth factor-dependent proliferation of clonogenic cells in AML. Blood 78: 1085-1095, 1991.
36. Hassan HT: Synergism between differentiation inducing agents: preclinical and clinical studies. In: The Pharmacology of Cell Differentiation. Rifkind RA (ed). Elsevier, Amsterdam, pp277-294, 1993.
37. Baumann MA, Paul CC and Grace MJ: Effects of Interleukin-5 on AML. Am J Hematol 39: 269-274, 1992.
38. Ema H, Kitano K, Suda T, et al: In vitro differentiation of leukemic cells to eosinophils in the presence of interleukin-5 in two cases of AML with the translocation t(8;21)(q22;q22). Blood 75: 350-356, 1990.
39. Touw I, Donath J, Pouwels K, et al: AML with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5. Leukemia 5: 687-692, 1991.
40. Miyauchi J, Sugita K, Okui M, et al: Differentiation induction of blast cells in two cases of childhood acute megakaryoblastic leukemia in vitro by IL-3 and IL-6: an ultrastructural cytochemical study. J Cell Physiol 148: 404-413, 1991.
41. Hassan HT, Grell S, Borrmann-Danso U and Freund M: Effect of recombinant human interferons in inducing differentiation of acute megakaryoblastic leukaemia blast cells. Leuk Lymphoma 16: 329-333, 1995.
42. Koistinen P, Wang C, Curtis JE, et al: GM-CSF and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 5: 789-795, 1991.
43. Kaplinsky C, Lotem J and Sachs L: Protection of human myeloid leukemia cells against doxorubicin-induced apoptosis by GM-CSF and interleukin-3. Leukemia 10: 460-465, 1996.
44. Hassan HT and Zander AR: Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 95: 257-262, 1996.
45. Demetri GD: Editorial: Beyond supportive care: What are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy? Blood 82: 2278-2280, 1993.
46. Büchner T, Hiddemann W, Koenigsmann M, et al: Recombinant human GM-CSF after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78: 1190-1197, 1991.
47. Estey EH, Dixon D, Kantarjian HM, et al: Treatment of poor-prognosis, newly diagnosed AML with Ara-C and recombinant human GM-CSF. Blood 75: 1766-1769, 1990.
48. Bernell P, Kimby E and Hast R: Recombinant human GM-CSF in combination with standard induction chemotherapy in AML evolving from MDS: a pilot study. Leukemia 8: 1631-1639, 1994.
49. Witz F, Harousseau Jl, Cahn JY, et al: GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Blood 84 (Suppl. 1): 231a, 908, 1994.
50. Stone RM, Berg DT, George SL, et al: GM-CSF after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332: 1671-1677, 1995.
51. Rowe JM, Andersen JW, Mazza JJ, et al: A randomised placebo-controlled phase III study of GM-CSF in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457-462, 1995.
52. Zittoun R, Suciu S, Mandelli F, et al: Recombinant human GM-CSF associated with induction treatment of acute myelogenous leukemia (AML). A randomised trial by the EORTC leukemia cooperative group. J Clin Oncol 14: 2150-2159, 1996.
53. Löwenberg B, Suciu S, Zittoun R, et al: GM-CSF during as well as after induction chemotherapy in elderly patients with AML: the EORTC-HOVON phase III trial (AML 11). Blood 86 (Suppl.): 1719, 1995.
54. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of G-CSF after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: 871-877, 1990.
55. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant G-CSF in elderly patients after treatment for AML. N Engl J Med 332: 1678-1683, 1995.
56. Godwin JE, Kopecky KJ, Head DR, et al: A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated AML. Blood 86 (Suppl.) 434A, 1995.
57. Heil G, Hoelzer D, Sanz, et al: Results of a randomised doubleblind placebo controlled phase III study of Filgristim in remission induction and early consolidation therapy for adults with de novo AML. Blood 86 (Suppl.) 267A, 1995.
58. Link H: The role of growth factors for the treatment of AML. Ann Hematol 74 (Suppl. 1): A1, 2, 1997.
59. Ohno R, Miyawaki S, Hatake K, et al: M-CSF reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation chemotherapy in AML. A double-blind controlled study. Blood 86 (Suppl. 1): 266a, 1050, 1995.
60. Gore SD, Weng LJ and Burke PJ: Biologic and clinical impact of growth factor augmentation of post-remission chemotherapy for AML. Blood 84 (Suppl. 1): 582a, 2313, 1994.
61. Geller RB, Tarantolo S, Powell BL, et al: Phase II study of PIXY321 in elderly patients with newly diagnosed AML. Blood 86 (Suppl. 1): 760a, 3026, 1995.
62. Bettelheim P, Valent P, Andreeff M, et al: Recombinant human GM-CSF in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77: 700-711, 1991.
63. Estey E, Thall PF, Kantarjian H, et al: Treatment of newly diagnosed AML with GM-CSF before and during continuous-infusion ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79: 2246-2255, 1992.
64. Büchner T, Hiddemann W, Wörmann B, et al: Hematoppietic growth factors in acute myeloid leukemia: supportive and priming effects. Semin Oncol 24: 124-131, 1997.
65. Heil G, Chadid L, Hoelzer D, et al: GM-CSF in a double-blind randomized placebo controlled trial in therapy of adult patients with de novo AML. Leukemia 9: 3-9, 1995.
66. Baer MR, Bernstein SH, Brunetto VL, et al: In vivo recombinant human G-CSF priming in previously untreated AML. Blood 82 (Suppl.): 328a, 26, 1993.
67. Estey E, Thall P and Andreeff M: Use of G-CSF before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed AML or MDS: comparison with fludarabine plus cytarabine without G-CSF. J Clin Oncol 12: 671-678, 1994.
68. Ohno R, Noae T, Kanamaru A, et al: A double-blind controlled study of G-CSF started 2 days before induction chemotherapy in refractory AML. Blood 84: 2086-2092, 1994.
69. Cortes J, Andreeff M, O'Brien S, et al: Use of interleukin-3 for sensitization to chemotherapy in relapsed or refractory AML. Blood 84 (Suppl.): 232a, 915, 1994.
70. Wielenga JJ, Vellenga E, Groenewegen A, et al: Recombinant human interleukin-3 in combination with remission induction chemotherapy in patients with relapsed AML: a phase I/II study. Leukemia 10: 43-47, 1996.
71. Feldman E, Geller RB, Seiter K, et al: PIXY321 in combination with high-dose cytarabine and mitoxantrone in poor prognosis AML. Blood 86 (Suppl. 1): 520a, 2068, 1995.
72. Kitano K, Kobayashi H, Maeyama H, et al: Treatment of acute monoblastic leukemia by combination of recombinant human M-CSF and low dose Ara-C. Br J Haematol 85: 176-178, 1993.
73. Foa R, Meloni G, Tosti S, et al: Treatment of acute myeloid leukaemia patients with recombinant interleukin-2: a pilot study. Br J Haematol 77: 491-496, 1991.
74. Maraninchi D, Blaise D, Viens P, et al: High-dose recombinant interleukin-2 and AML in relapse. Blood 78: 2182-2187, 1991.
75. Lim SH, Newland AC, Kelsey S, et al: Continuous intravenous infusion of high-dose recombinant human interleukin-2 for AML-a phase II study. Cancer Immunol Immunother 34: 337-342, 1992.
76. Meloni G, Foa R, Vignetti M, et al: Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84: 2158-2163, 1994.
77. Bergmann L, Heil G, Kolbe K, et al: Interleukin-2 bolus infusion as late consolidation therapy in second remission of AML. Leuk Lymphoma 16: 271-279, 1995.
78. Benyunes MC, Massumoto C, York A, et al: Interleukin-2 with or without LAK cells as consolidative immunotherapy after autologous BMT for AML. Bone Marrow Transplant 12: 159-163, 1993.
79. Hamon MD, Prentice HG, Gottlieb DJ, et al: Immunotherapy with interleukin-2 after ABMT in AML. Bone Marrow Transplant 11: 399-401, 1993.
80. Fefer A, Benyunes M, Higuichi C, et al: Interleukin-2 +/-lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol 89 (suppl 1): 2-7, 1993.
81. Klingemann H-G, Eaves CJ, Barnett MJ, et al: Transplantation of patients with high-risk AML in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 14: 389-396, 1994.
82. Zühlsdorf M, Brandt M and Büchner T: PIXY321 and G-CSF superior to GM-CSF, IL-3 or IL-1 as growth factors in priming AML-colony forming cells for Ara-C. Blood 86 (Suppl. 1): 706a, 2813, 1995.
83. Estey E and Andreeff M: Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia. Leukemia 9: 1440-1443, 1995.
84. Baer MR, Bernstein SH, Brunetto VL, et al: Biological effects of recombinant human G-CSF in patients with untreated AML. Blood 87: 1484-1494, 1996.